JP2025504382A5 - - Google Patents

Info

Publication number
JP2025504382A5
JP2025504382A5 JP2024540933A JP2024540933A JP2025504382A5 JP 2025504382 A5 JP2025504382 A5 JP 2025504382A5 JP 2024540933 A JP2024540933 A JP 2024540933A JP 2024540933 A JP2024540933 A JP 2024540933A JP 2025504382 A5 JP2025504382 A5 JP 2025504382A5
Authority
JP
Japan
Prior art keywords
azacycloundecine
methoxytetrahydro
oxazepine
pyrazino
decahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024540933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504382A (ja
JP7714811B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/060944 external-priority patent/WO2023141536A1/en
Publication of JP2025504382A publication Critical patent/JP2025504382A/ja
Publication of JP2025504382A5 publication Critical patent/JP2025504382A5/ja
Priority to JP2025118767A priority Critical patent/JP2025160251A/ja
Application granted granted Critical
Publication of JP7714811B2 publication Critical patent/JP7714811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024540933A 2022-01-21 2023-01-20 1,3,4,7-テトラヒドロ-2H-ピロロ[3’,2’:5,6]ピリド[2,3-B][1,4]オキサアゼピンBcl-2阻害剤 Active JP7714811B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025118767A JP2025160251A (ja) 2022-01-21 2025-07-15 1,3,4,7-テトラヒドロ-2H-ピロロ[3’,2’:5,6]ピリド[2,3-B][1,4]オキサアゼピンBcl-2阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267018P 2022-01-21 2022-01-21
US63/267,018 2022-01-21
PCT/US2023/060944 WO2023141536A1 (en) 2022-01-21 2023-01-20 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025118767A Division JP2025160251A (ja) 2022-01-21 2025-07-15 1,3,4,7-テトラヒドロ-2H-ピロロ[3’,2’:5,6]ピリド[2,3-B][1,4]オキサアゼピンBcl-2阻害剤

Publications (3)

Publication Number Publication Date
JP2025504382A JP2025504382A (ja) 2025-02-12
JP2025504382A5 true JP2025504382A5 (cg-RX-API-DMAC7.html) 2025-06-09
JP7714811B2 JP7714811B2 (ja) 2025-07-29

Family

ID=85382827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024540933A Active JP7714811B2 (ja) 2022-01-21 2023-01-20 1,3,4,7-テトラヒドロ-2H-ピロロ[3’,2’:5,6]ピリド[2,3-B][1,4]オキサアゼピンBcl-2阻害剤
JP2025118767A Pending JP2025160251A (ja) 2022-01-21 2025-07-15 1,3,4,7-テトラヒドロ-2H-ピロロ[3’,2’:5,6]ピリド[2,3-B][1,4]オキサアゼピンBcl-2阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025118767A Pending JP2025160251A (ja) 2022-01-21 2025-07-15 1,3,4,7-テトラヒドロ-2H-ピロロ[3’,2’:5,6]ピリド[2,3-B][1,4]オキサアゼピンBcl-2阻害剤

Country Status (13)

Country Link
US (3) US11964990B2 (cg-RX-API-DMAC7.html)
EP (1) EP4466273A1 (cg-RX-API-DMAC7.html)
JP (2) JP7714811B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240136972A (cg-RX-API-DMAC7.html)
CN (1) CN119053610A (cg-RX-API-DMAC7.html)
AR (1) AR128310A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023210279A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242074A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009334A2 (cg-RX-API-DMAC7.html)
IL (1) IL312709A (cg-RX-API-DMAC7.html)
MX (1) MX2024008840A (cg-RX-API-DMAC7.html)
TW (1) TW202340210A (cg-RX-API-DMAC7.html)
WO (1) WO2023141536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑
CN117820134A (zh) * 2024-01-10 2024-04-05 山东盛安贝新材料有限公司南京分公司 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002032A (es) 2017-08-23 2020-09-17 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de bcl-2.
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
MX2022010410A (es) 2020-02-24 2022-12-07 Guangzhou Lupeng Pharmaceutical Company Ltd Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑

Similar Documents

Publication Publication Date Title
FI3672975T3 (fi) Kondensoituja heterosyklisiä johdannaisia bcl-2-inhibiittoreina neoplastisten sairauksien hoitamiseksi
JP2023027344A5 (cg-RX-API-DMAC7.html)
US9056859B2 (en) Inhibitors of the renal outer medullary potassium channel
JP2018168191A5 (cg-RX-API-DMAC7.html)
JP2009539958A5 (cg-RX-API-DMAC7.html)
JP2010535640A5 (cg-RX-API-DMAC7.html)
JP2009538861A5 (cg-RX-API-DMAC7.html)
CA2534024A1 (en) Novel compounds having inhibitory activity against sodium-dependant transporter
WO2013066714A1 (en) Inhibitors of the renal outer medullary potassium channel
AR061652A1 (es) Derivados de pirimidina, un metodo para su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de gsk3.
PE20160043A1 (es) Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2
JP2005526753A5 (cg-RX-API-DMAC7.html)
MX2010006260A (es) Composiciones orales de abt-263 para tratar cancer.
WO2007103456A3 (en) Piperazine and piperidine biaryl derivatives
JP2009541443A5 (cg-RX-API-DMAC7.html)
DOP2013000169A (es) Compuesto para uso en el tratamiento de la artritis
JP2007516193A5 (cg-RX-API-DMAC7.html)
ES2523518T3 (es) Nuevas combinaciones farmacológicas para el tratamiento de enfermedades de las vías respiratorias
JP2004509099A5 (cg-RX-API-DMAC7.html)
BRPI0417714A (pt) composto, composição farmacêutica, e, uso de um composto
EP3207030A1 (en) Inhibitors of the renal outer medullary potassium channel
JP2004501921A5 (cg-RX-API-DMAC7.html)
AR056218A1 (es) Composicion farmaceutica de liberacion mantenida comprimido de liberacion inmediata y comprimido oralmente administrable que comprende una sla soluble en agua d 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2- hidroxi-1-(hidroximetil)etil] amino}pirido (2,3-d)pirimidin-7(8h)-ona; dicho compues
GEP20074272B (en) Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction
JP5321375B2 (ja) ゴルフクラブヘッド